Stefani Wolff
Nessuna posizione attualmente
Patrimonio netto: 89 861 $ in data 31/03/2024
Profilo
Stefani A.
Wolff worked as a Product Manager at Eli Lilly & Co. from 1989 to 1997.
She then worked as a Senior Director at Genentech, Inc. from 2007 to 2010.
In 2013, she became the Vice President-Development at Onyx Pharmaceuticals, Inc. and later served as the Chief Development Officer at Principia Biopharma, Inc. from 2018 to 2020.
In 2021, she became an Independent Director at Rain Oncology, Inc. and the Chief Operating Officer & EVP-Product Development at Nurix Therapeutics, Inc. She also worked as a Principal at BioPharma Consulting Services LLC in 2016-2017.
Wolff received her undergraduate degree from The University of North Carolina at Charlotte in 1989.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
NURIX THERAPEUTICS, INC.
0.01% | 01/05/2023 | 6 113 ( 0.01% ) | 89 861 $ | 31/03/2024 |
Precedenti posizioni note di Stefani Wolff
| Società | Posizione | Fine |
|---|---|---|
| RAIN ONCOLOGY INC. | Director/Board Member | 25/01/2024 |
| NURIX THERAPEUTICS, INC. | Chief Operating Officer | 02/05/2023 |
| PRINCIPIA BIOPHARMA INC. | Corporate Officer/Principal | 28/09/2020 |
| BioPharma Consulting Services LLC | Corporate Officer/Principal | 01/01/2017 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 01/12/2015 |
Formazione di Stefani Wolff
| The University of North Carolina at Charlotte | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| NURIX THERAPEUTICS, INC. | Health Technology |
| Aziende private | 5 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
| BioPharma Consulting Services LLC | |
Rain Oncology, Inc.
 Rain Oncology, Inc. BiotechnologyHealth Technology Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for patients suffering from cancer. The company was founded by Avanish Vellanki and Robert Doebele in April 2017 and is headquartered in Newark, CA. | Health Technology |
- Borsa valori
- Insiders
- Stefani Wolff
